Trial Profile
A Single Stage Phase II, Multi-centre, Open Label Study of Imatinib in Combination With Pioglitazone, Etoricoxib, Dexamethasone and Low-dose Treosulfane for Anti-inflammatory and Angiostatic Treatment in Patients With Hormone-refractory Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Dexamethasone; Etoricoxib; Pioglitazone; Treosulfan
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 29 Aug 2015 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
- 05 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 according to ClinicalTrials.gov record.
- 05 Jan 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015 according to ClinicalTrials.gov record.